ELR510444 |
Catalog No.GC16827 |
ELR510444 est un nouveau perturbateur de microtubules; inhibe la prolifération des cellules MDA-MB-231 avec une IC50 de 30,9 nM; n'est pas un substrat pour le transporteur de médicaments de la glycoprotéine P et conserve son activité dans les lignées cellulaires surexprimant la βIII-tubuline.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1233948-35-0
Sample solution is provided at 25 µL, 10mM.
Microtubules are involved in nucleic and cell organization, division of intracellular structure, and intracellular transport, as well as ciliary and flagellar motility. Microtubule-targeting agents are some of the most effective chemotherapeutic drugs used in the clinic today. ELR510444 is a novel microtubule disruptor with multiple mechanisms of action.
In vitro: ELR510444 has potent microtubuledisrupting activity, causing a loss of intracellular microtubules and the formation of aberrant mitotic spindles and leading to mitotic arrest and apoptosis of cancer cells. ELR510444 inhibited cell proliferation, inhibited the rate and extent of purified tubulin assembly potently, and displaced colchicine from tubulin, revealing that the drug directly interacts with tubulin at the colchicine-binding site [1].
In vivo: ELR510444 also shows potent antitumor activity in the MDA-MB-231 xenograft model with at least a 2-fold therapeutic window [1].
Clinical trial: Up to now, ELR510444 is still in the preclinical development stage.
Reference:
[1] Risinger AL, Westbrook CD, Encinas A, Mülbaier M, Schultes CM, Wawro S, Lewis JD, Janssen B, Giles FJ, Mooberry SL. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther. 2011 Mar;336(3):652-60.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *